Skip to main
RNAC
RNAC logo

RNAC Stock Forecast & Price Target

RNAC Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cartesian Therapeutics Inc. is projected to demonstrate positive outcomes in its Phase 3 myasthenia gravis (MG) trial, bolstered by impressive Phase 2 results, which indicate a strong potential for market penetration reaching approximately 30% in the U.S. and 20% in the EU5 by 2037. The well-tolerated nature of Descartes-08 allows for outpatient administration without requiring lymphodepleting chemotherapy, enhancing its attractiveness in the clinical setting. Additionally, the company's ongoing research into other autoimmune diseases, such as systemic lupus erythematosus (SLE) and pediatric indications, underscores its commitment to expanding its therapeutic portfolio, while the favorable durability and stability observed in responses further support a positive long-term outlook for Cartesian Therapeutics.

Bears say

Cartesian Therapeutics Inc reported a net loss of $0.40 per share for Q4 2024, indicating ongoing financial challenges as the company continues to invest in its clinical-stage initiatives. The variable efficacy of its lead product, Vyvgart, which shows diminished benefits that require frequent re-treatment, raises concerns about the long-term viability of product uptake and market acceptance. Additionally, outlined risks, including potential delays in clinical trials, the need for favorable clinical data from ongoing studies, and the possibility of long-term dilution, contribute to a negative outlook for the company's financial stability moving forward.

RNAC has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cartesian Therapeutics Inc (RNAC) Forecast

Analysts have given RNAC a Buy based on their latest research and market trends.

According to 1 analysts, RNAC has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cartesian Therapeutics Inc (RNAC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.